Evidence map›Paper›PMID 42864417›Full record

ArticleLeukemia2026

PHI-101: a novel FLT3 inhibitor with potent activity against the F691L gatekeeper resistance mutation.

Marina Mitrou, Li Li, Bao Ho Nguyen, Gi-Jun Sung, Ky-Youb Nam, Kyu-Tae Kim, Jeong-Hyeok Yoon, Michelle Wang, David Young, Ruiqi Zhu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marina MitrouDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Li LiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bao Ho NguyenDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gi-Jun SungPharos iBio Co. Ltd, Seoul, Republic of Korea.
Ky-Youb NamPharos iBio Co. Ltd, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-9450-9953
Kyu-Tae KimPharos iBio Co. Ltd, Seoul, Republic of Korea.
Jeong-Hyeok YoonPharos iBio Co. Ltd, Seoul, Republic of Korea.
Michelle WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David YoungDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0885-8568
Ruiqi ZhuDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tessa SealeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Seung-Hye ChoiDepartment of Medical Science, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
Taebo SimDepartment of Medical Science, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
Donald SmallDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. donsmall@jhmi.edu.ORCID http://orcid.org/0009-0006-3410-7000

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42864417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.